Lymphoma: all 5,624 studies

Page 18 of 57. Open to participants first (824), then studies with results posted, then the rest; newest registration first within each.

• Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular LymphomaTerminatedNCT00901927Phase 2Results posted
• Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's LymphomaTerminatedNCT00901303Not applicableResults posted
• Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell LymphomaCompletedNCT00896493Phase 2Results posted
• Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum CalciumCompletedNCT00896454Phase 2Results posted
• High Dose Rituximab for Initial Treatment of Indolent B-Cell LymphomasCompletedNCT00895661Phase 2Results posted
• A Study of IXAZOMIB in Adult Patients With LymphomaCompletedNCT00893464Phase 1Results posted
• Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell LymphomaCompletedNCT00891839Phase 2Results posted
• Acupuncture for Chemo-Induced Peripheral NeuropathyCompletedNCT00891618Phase 2Results posted
• Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell LymphomaCompletedNCT00888927Phase 1/2Results posted
• Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin LymphomaCompletedNCT00884286Phase 2Results posted
• Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic LeukemiaTerminatedNCT00882206Phase 2Results posted
• A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell LymphomasCompletedNCT00880581Phase 2Results posted
• Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT StudyCompletedNCT00877006Phase 3Results posted
• A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)CompletedNCT00875667Phase 2Results posted
• Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)CompletedNCT00875056Phase 2Results posted
• Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT00873457Phase 2Results posted
• Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaCompletedNCT00873093Phase 2Results posted
• Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell LymphomaCompletedNCT00869999Phase 2Results posted
• Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins LymphomaCompletedNCT00868608Phase 2Results posted
• Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell LymphomaCompletedNCT00867529Phase 2Results posted
• Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's LymphomaCompletedNCT00867087Phase 2Results posted
• Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic LymphomaCompletedNCT00866749Phase 2Results posted
• A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's LymphomaTerminatedNCT00866333Phase 2Results posted
• A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell LymphomaCompletedNCT00866047Phase 2Results posted
• Belinostat in Relapsed or Refractory Peripheral T-Cell LymphomaCompletedNCT00865969Phase 2Results posted
• Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)CompletedNCT00864227Phase 2Results posted
• Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin LymphomaCompletedNCT00863369Phase 1/2Results posted
• Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaTerminatedNCT00860171Phase 1Results posted
• Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure DisordersCompletedNCT00856388Not applicableResults posted
• Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular LymphomaCompletedNCT00856245Phase 2Results posted
• Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/LymphomaTerminatedNCT00854581Phase 4Results posted
• Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to TreatmentTerminatedNCT00851552Phase 2Results posted
• Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With RituximabTerminatedNCT00850499Phase 2Results posted
• Proton Therapy for Hodgkin LymphomaCompletedNCT00850200Not applicableResults posted
• Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)TerminatedNCT00849524Phase 2Results posted
• Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)CompletedNCT00849147Phase 2Results posted
• A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin LymphomaCompletedNCT00848926Phase 2Results posted
• A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell LymphomaTerminatedNCT00843050Phase 2Results posted
• Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid MalignanciesTerminatedNCT00837200Phase 2Results posted
• Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic CancerTerminatedNCT00827099Phase 2Results posted
• Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)CompletedNCT00823719Phase 2Results posted
• S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin LymphomaCompletedNCT00822120Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic CancerTerminatedNCT00818961Phase 2Results posted
• Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00816595Phase 2Results posted
• Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's LymphomaTerminatedNCT00810576Phase 2Results posted
• R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's LymphomaTerminatedNCT00809341Phase 2Results posted
• Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCYCompletedNCT00809276Phase 1/2Results posted
• Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's LymphomaCompletedNCT00807495Phase 2Results posted
• Autologous and Allogeneic Transplant for Relapsed LymphomaCompletedNCT00802113Phase 1/2Results posted
• High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System InvolvementCompletedNCT00801216Phase 2Results posted
• Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell LymphomaCompletedNCT00799513Phase 2Results posted
• Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell LymphomaCompletedNCT00798096Phase 2Results posted
• Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell TransplantCompletedNCT00795769Phase 2Results posted
• Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's LymphomaCompletedNCT00792467Phase 1/2Results posted
• Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapyCompletedNCT00790036Phase 3Results posted
• Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic CancerCompletedNCT00789776Phase 1/2Results posted
• Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid TumorsTerminatedNCT00788125Phase 1/2Results posted
• Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological CancerCompletedNCT00787761Phase 2Results posted
• SAHA + CHOP in Untreated T-cell Non-Hodgkin's LymphomaCompletedNCT00787527Phase 1/2Results posted
• Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory LymphomasTerminatedNCT00785798Phase 1/2Results posted
• Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin LymphomaCompletedNCT00784927Phase 2Results posted
• Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell LymphomasCompletedNCT00783367Phase 2Results posted
• Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic CancerCompletedNCT00782379Phase 2Results posted
• A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248)CompletedNCT00779584Phase 1Results posted
• 18F- Fluorothymidine to Evaluate Treatment Response in LymphomaTerminatedNCT00775268Phase 1/2Results posted
• Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZLTerminatedNCT00772668Not applicableResults posted
• Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)CompletedNCT00771472Phase 1Results posted
• S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin LymphomaCompletedNCT00770224Phase 2Results posted
• Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin LymphomaCompletedNCT00765245Phase 2Results posted
• Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's LymphomaCompletedNCT00764517Phase 2Results posted
• Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure DisorderCompletedNCT00755040Phase 3Results posted
• A Study for Participants With Relapsed Cutaneous T-Cell LymphomaCompletedNCT00744991Phase 2Results posted
• Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's LymphomaCompletedNCT00742027Phase 2Results posted
• Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.CompletedNCT00739141Phase 2Results posted
• A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" TrialCompletedNCT00737529Phase 2Results posted
• Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell LymphomaTerminatedNCT00736450Early Phase 1Results posted
• Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With LymphomaCompletedNCT00733824Phase 1/2Results posted
• Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHLCompletedNCT00732498Phase 2Results posted
• Methadone, Morphine, or Oxycodone in Treating Pain in Patients With CancerTerminatedNCT00726830Not applicableResults posted
• Study of the Safety and Tolerability of PCI-24781 in Patients With LymphomaCompletedNCT00724984Phase 1/2Results posted
• Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And RituximabCompletedNCT00724971Phase 1Results posted
• Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCLTerminatedNCT00724061Not applicableResults posted
• Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerCompletedNCT00723099Phase 2Results posted
• Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin LymphomaTerminatedNCT00722865Phase 2Results posted
• Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell LymphomaCompletedNCT00722137Phase 3Results posted
• Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin LymphomaCompletedNCT00720876Phase 2Results posted
• Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic DiseaseCompletedNCT00719888Phase 2Results posted
• Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other DiseaseTerminatedNCT00719849Phase 2Results posted
• American Ginseng in Treating Patients With Fatigue Caused by CancerCompletedNCT00719563Phase 3Results posted
• A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)CompletedNCT00719472Phase 3Results posted
• Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular LymphomaCompletedNCT00715208Phase 2Results posted
• Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell MalignanciesTerminatedNCT00714259Phase 2/3Results posted
• Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell LymphomaCompletedNCT00712582Phase 2Results posted
• Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell LymphomaCompletedNCT00711828Phase 2Results posted
• Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCTCompletedNCT00709592Phase 2Results posted
• Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or LymphomaCompletedNCT00705874Phase 1Results posted
• Bendamustine HCL in Relapsed and Primary Refractory Hodgkin LymphomaCompletedNCT00705250Phase 2Results posted
• Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell LymphomaCompletedNCT00703664Phase 2Results posted
• Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® TherapyCompletedNCT00702052Phase 2Results posted
• Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]CompletedNCT00700258Results posted

← Lymphoma overview